Enzyme fragment complementation: A flexible high throughput screening assay technology

被引:73
作者
Eglen, RM [1 ]
机构
[1] DiscoveRx Corp, Fremont, CA 94538 USA
关键词
D O I
10.1089/154065802761001356
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
High-affinity complementation of a small fragment of beta-galactosidase to an inactive deletion mutant of the enzyme forms a stable heteromeric enzyme complex capable of hydrolyzing substrates to produce either chemiluminescent or fluorescent signals. This review describes a series of screening assays in which the small beta-galactosidase fragment, Enzyme Donor or ProLabel, is either chemically conjugated or recombinantly fused to small molecules or proteins, respectively. Chemical conjugation forms the basis of several HitHunter(TM) HTS assays in which competitive displacement of the ProLabel conjugate from either a binding protein ( receptor or antibody) is induced by the analyte in question. In this manner, a calibration curve is generated, to measure cellular analytes including 3',5'-cyclic AMP. Changes in this second messenger, occurring due to G protein-coupled receptor ( GPCR) activation, can thus be easily measured in a homogeneous assay. Similar assays have been developed for tyrosine kinases, serine threonine kinases, nuclear hormone receptors, and proteases. A second form of assay technology involves measurement of cellular protein expression, in which the protein is fused to ProLabel. Analysis can be undertaken in crude cell lysates, or with intact cells, using beta-galactosidase complementation in a microtiter plate. This homogeneous technology is highly sensitive and has been developed to measure protein expression changes occurring in response to pathway activation by targets such as GPCRs, tyrosine kinase receptors, and proteases. In summary, the DiscoveRx technology using beta-galactosidase complementation provides a robust and flexible assay technology for use in cell-free and cell-based HTS.
引用
收藏
页码:97 / 104
页数:8
相关论文
共 35 条
[1]   Proteasome inhibition: a novel approach to cancer therapy [J].
Adams, J .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S49-S54
[2]  
Auerbach D, 2002, PROTEOMICS, V2, P611, DOI 10.1002/1615-9861(200206)2:6<611::AID-PROT611>3.0.CO
[3]  
2-Y
[4]  
Bohm SK, 1997, BIOCHEM J, V322, P1
[5]   The ubiquitin-proteasome pathway: on protein death and cell life [J].
Ciechanover, A .
EMBO JOURNAL, 1998, 17 (24) :7151-7160
[6]   Protease-activated receptors: sentries for inflammation? [J].
Cocks, TM ;
Moffatt, JD .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (03) :103-108
[7]  
COTY WA, 1994, J CLIN IMMUNOASSAY, V17, P144
[8]  
Coty WA, 1999, GENET ENG NEWS, V19, P26
[9]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[10]   Importance of the regulation of nuclear receptor degradation [J].
Dennis, AP ;
Haq, RU ;
Nawaz, Z .
FRONTIERS IN BIOSCIENCE, 2001, 6 :D954-D959